Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Present with mild AD dementia based on the National Institute on Aging (NIA) and the Alzheimer's Association (AA) disease diagnostic criteria as determined by a qualified clinician approved by the Sponsor or designee.~* Mini-Mental State Examination score of 20 to 26 inclusive at screening visit.~* Has a florbetapir PET scan consistent with the presence of amyloid pathology at screening.~Exclusion Criteria:~* Significant neurological disease affecting the central nervous system (CNS), other than AD, that may affect cognition or ability to complete the study, including but not limited to, other dementias, serious infection of the brain, Parkinson's disease, multiple concussions, or epilepsy or recurrent seizures (except febrile childhood seizures).~* Ocular pathology that significantly limits ability to reliably evaluate vision or the retina.~* Use of strong inducers of cytochrome P450 3A (CYP3A).~* Sensitivity to florbetapir or ¹⁸F-AV-1451.~* Contraindication to MRI or PET or poor venous access for blood draws.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Dose 1 LY3202626 (Type: EXPERIMENTAL): 3 mg LY3202626 given orally once daily for 52 weeks.
- Dose 2 LY3202626 (Type: EXPERIMENTAL): 12 mg LY3202626 given orally once daily for 52 weeks.
- Placebo (Type: EXPERIMENTAL): Placebo given orally once daily for 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).